The Billion Dollar Weight-Loss Market

In the early 1990s, a Bronx VA endocrinologist went looking for the reason a venomous lizard could go months without eating. What he found eventually became Ozempic, Wegovy, Mounjaro and a class of drugs now reshaping diabetes care, obesity treatment, pharmaceutical balance sheets, and this year, for the first time, the price a patient in India pays for a monthly injection. This piece pulls that whole arc together, including the India-specific numbers, and ends with a plain framework for deciding whether one of these drugs actually makes sense for you.

The venom that didn't fit the textbook

In the early 1990s, Dr John Eng, an endocrinologist working at the Bronx VA Medical Center, was studying the venom of the Gila monster, a slow-moving lizard native to the American Southwest. The animal had an odd trait: it could go three to four months between meals and still keep its blood sugar stable. Eng ordered dried venom from a Utah supplier and, working with a colleague who ferried test tubes across New York City in his car, isolated a 39-amino-acid peptide he named exendin-4.

Exendin-4 turned out to be roughly 53 percent structurally similar to a human gut hormone called glucagon-like peptide-1, or GLP-1. Human GLP-1 does useful things! It tells the pancreas to release insulin after a meal, slows down how fast the stomach empties, and dampens appetite — but it barely lasts two minutes in the bloodstream before an enzyme called DPP-4 breaks it down. Exendin-4, because of its slightly different structure, resisted that enzyme and lasted for hours. It was, in effect, a version of the body's own appetite-and-blood-sugar hormone that didn't disappear before it could work.

Eng licensed the discovery to Amylin Pharmaceuticals, which partnered with Eli Lilly to build a synthetic copy called exenatide. The FDA approved it in 2005 under the brand name Byetta — the first GLP-1 receptor agonist ever approved for human use. Patients and journalists nicknamed it "lizard spit." It required two injections a day and was, by later standards, a blunt instrument. But it proved the concept worked, and in 2012 the US Congress gave Eng a Golden Goose Award, a prize specifically for odd-sounding research that produced outsized public benefit.

A side effect nobody was seeing

Byetta was built and approved as a diabetes drug. Its job was to lower blood sugar. But endocrinologists running the early trials noticed something else: patients on exenatide were losing weight, and not as a side note buried in a rash of gastrointestinal complaints — meaningfully, consistently, in a way other diabetes drugs of the era did not produce. GLP-1's appetite-suppressing and stomach-emptying effects, it turned out, mattered as much outside the bloodstream as inside it.

That observation didn't immediately change anything. It took a decade of incremental drug development — longer-acting molecules, weekly dosing instead of daily, higher and better-tolerated doses — before the weight-loss effect became the headline rather than the footnote.

The pivot nobody planned for

Novo Nordisk's liraglutide, sold as Saxenda, became the first GLP-1 drug specifically approved for obesity in 2014. It was still a daily injection and didn't attract much public attention. Two years later, the same company's semaglutide molecule was approved for type 2 diabetes as a once-weekly injection called Ozempic. The convenience mattered, and so did the potency. Off-label use for weight loss — doctors prescribing a diabetes drug to non-diabetic patients because of its appetite effects — grew quietly at first, then loudly once celebrities and social media started talking about it.

Novo formalised what was already happening in doctors' offices. Following the STEP 1 trial, the FDA approved semaglutide specifically for chronic weight management in June 2021, under a new brand name: Wegovy. A follow-up trial released in 2025, testing a higher 7.2 mg dose, found average weight loss of 21 percent over 72 weeks in people without diabetes, with more than 90 percent of participants losing at least 5 percent of their body weight. In March 2024, the FDA further approved Wegovy to reduce the risk of heart attack, stroke and cardiovascular death in people with obesity or overweight and existing heart disease — pushing the drug's identity well past "weight loss" and into general cardiometabolic medicine.

Semaglutide also went oral. Rybelsus, an earlier daily pill version, had modest efficacy. A more potent oral Wegovy tablet, tested in the OASIS 4 trial, produced 13.6 to 16.6 percent average weight loss (the range reflects whether all participants stayed on treatment) and received FDA approval in December 2025, launching in the US in January 2026 at a cash price of $149 a month for the lowest doses and up to $299 for the highest — with a $25-a-month price available to some insured patients.

Eli Lilly's dual-hormone answer

While Novo Nordisk built an empire on semaglutide, Eli Lilly took a different molecular route with tirzepatide, a compound that activates both the GLP-1 receptor and a second gut hormone receptor, GIP. The dual action produced markedly stronger results in trials. Lilly launched it for diabetes as Mounjaro in 2022 and for obesity as Zepbound shortly after.

The commercial numbers that followed are hard to overstate. In 2025, combined sales of Mounjaro and Zepbound reached $36.5 billion, making tirzepatide the world's best-selling drug — ahead of Novo's combined semaglutide portfolio at $33 billion and Merck's cancer drug Keytruda at $31.7 billion. In the fourth quarter of 2025 alone, Zepbound sales grew 123 percent year-on-year to $4.26 billion, outpacing Wegovy's 17-percent growth to $3.46 billion in the same quarter. Lilly closed 2025 with $65.2 billion in total revenue and told investors to expect more than $80 billion in 2026, driven substantially by this one drug class.

Lilly followed Novo into oral GLP-1 territory too, but with a technical advantage. Its pill, orforglipron, is a small molecule rather than a fragile oral peptide, so it doesn't need to be taken on an empty stomach with only water, the way Novo's semaglutide tablet does. The FDA approved it on 1 April 2026 under the brand name Foundayo — the first GLP-1 pill with no food or water timing restrictions — priced from $149 to $399 a month for cash-paying patients, undercut almost immediately by Novo's own decision to price its pill as low as $149.

What this looks like from India

India's stake in this story is not incidental, and it is where most international coverage of GLP-1 drugs stops short. The country carries one of the largest diabetes burdens in the world: the ICMR-INDIAB national study, published in The Lancet Diabetes & Endocrinology in 2023, estimated that more than 101 million Indians have diabetes and another 136 million have prediabetes, with generalised obesity affecting 28.6 percent of the study population and abdominal obesity 39.5 percent. That is the demand side of the story, and it is enormous.

The supply side arrived late and then all at once. Novo Nordisk launched Wegovy in India in 2025, initially priced between roughly ₹10,850 and ₹16,400 a month depending on dose. Ozempic followed in early 2026, priced from around $24 a week at the entry dose — a launch timed, by the company's own account, to establish itself before cheaper domestic competition arrived. Eli Lilly moved in parallel: Mounjaro, launched in India in March 2025, generated ₹80 crore in sales in September of that year alone and ₹233 crore cumulatively since launch, briefly making it the country's second-best-selling drug by that measure in a single month. In October 2025, Lilly partnered with Cipla to distribute a second tirzepatide brand, Yurpeak, priced identically to Mounjaro to widen its retail reach.

Then the patent cliff hit. Novo Nordisk's semaglutide patent expired in India on 20 March 2026, and more than 40 Indian drugmakers — Sun Pharma, Dr Reddy's, Cipla, Biocon, Mankind, and a Lupin–Zydus tie-up among them — moved to launch generic versions within days. Some priced starter doses as low as ₹1,290 a month. Natco Pharma's vial formulation launched at ₹1,250 a month; Alkem Laboratories' prefilled pen came in slightly higher at ₹1,800. Dr Reddy's had earlier told Reuters it expected to price its version 50 to 60 percent below Novo's branded cost. Novo responded with its own cuts — a roughly 37-percent reduction to Wegovy's price ahead of the patent expiry, followed by a further cut of up to 48 percent afterward, bringing its starter dose down to about ₹5,660 a month even as its top dose still runs to roughly ₹14,000–16,400.

The net effect is a market that did not exist anywhere else in the world at this scale as of mid-2026: branded semaglutide, a licensed second brand of tirzepatide, and dozens of domestic generic semaglutide products, all legally available in the same pharmacies within months of each other, at prices ranging across more than a ten-fold spread for what is, chemically, the same or a closely related molecule. Analysts estimate the global weight-loss drug market could approach $150 billion annually by the end of the decade, and India's combination of disease burden, generics manufacturing capacity, and now patent-free access makes it one of the more closely watched battlegrounds for who ends up serving that demand — and at what price.

What the price tag doesn't tell you

The most common side effects across this entire drug class are gastrointestinal — nausea, vomiting, diarrhoea and constipation — and they affect a meaningful share of users, particularly during the dose-escalation weeks. Most of this is described in trials as mild to moderate and transient.

Three other effects deserve more space than they usually get. The first is cosmetic and has acquired the nickname "Ozempic face": rapid fat loss, especially when it happens fast and in large amounts, can leave the face looking hollow and the skin loose, because facial fat pads shrink faster than skin can tighten. Doctors' advice is consistent — slower weight loss, adequate protein intake, and resistance training reduce the effect, and it can be corrected afterward with aesthetic treatment if it bothers a patient enough.

The second is muscle loss, and it is less settled than the cosmetic question. Some of the weight GLP-1 drugs remove is lean mass, not fat, which matters more for older patients or anyone already at risk of frailty. A dedicated observational trial at the University of Alberta, using MRI to separately track fat and muscle over 12 months of semaglutide use, was still recruiting as of late 2025 — a sign that the research establishment considers this an open question rather than a settled footnote, not a reason to avoid the drugs but a reason to pair them with strength training and enough protein.

The third is eye risk, and it is a useful case study in how a single alarming number can travel faster than its context. A 2024 retrospective study from Massachusetts Eye and Ear and Harvard Medical School, covering a modest 1,700-odd patients, found that patients on semaglutide developed a rare condition called non-arteritic anterior ischemic optic neuropathy (NAION) — sudden, often permanent vision loss from disrupted blood flow to the optic nerve — at notably higher rates than similar patients on other medicines: a cumulative incidence of 8.9 percent over three years among diabetic patients on semaglutide, against 1.8 percent on comparator drugs, and 6.7 percent against 0.8 percent among the overweight or obese group. Those numbers went viral. A larger, later database study from Stanford and the US Department of Veterans Affairs, covering hundreds of thousands of patient records, still found a statistically real doubling of relative risk, but put the actual absolute rate far lower — around 29 cases per 10,000 patient-years. Both studies are real; they measured different populations at different scales, and the second is closer to what an average patient should expect the odds to look like. The FDA has not withdrawn or restricted the drugs over this, but it is a fair question to raise with a prescriber, especially for anyone with existing eye disease.

Rarer still, but documented: acute pancreatitis, prompting a UK safety review; a boxed warning across the whole drug class — including Foundayo — for thyroid C-cell tumours, based on rodent studies, which rules the drugs out for anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome. And there is the supply-driven problem of compounded and counterfeit products: shortages between 2022 and 2024 pushed patients toward compounding pharmacies making unapproved versions, some using different salt forms of semaglutide that behave differently in the body, and the FDA has documented cases of contamination, including at least one pen found to contain a different diabetes drug entirely. Novo Nordisk's India head has told Reuters the company is aware of counterfeit sellers in the country but has struggled to trace and act against them.

Finally, the discontinuation problem. Extension data from the STEP trials show that most patients who stop semaglutide regain roughly 60 percent of the weight they lost within about a year. That single fact is doing a lot of quiet work in how doctors now talk about these drugs — less as a course of treatment with an endpoint, more as a chronic therapy similar to a blood pressure or cholesterol medicine, to be continued indefinitely or not started with an expectation of stopping.

Where the world is headed next

Three trends are visible in the pipeline right now.

The first is the move to pills: Wegovy's tablet and Lilly's Foundayo both launched within four months of each other in the US, and the absence of needles is likely to widen the pool of people willing to start treatment, even though oral versions generally produce somewhat less weight loss than the injectable originals.

The second is combination and multi-hormone therapy pushing past what single-hormone GLP-1 drugs can do. Novo's CagriSema, which pairs semaglutide with a second hormone called cagrilintide, produced an estimated 18.4 percent average weight loss in the REDEFINE 5 trial published in The Lancet in April 2026, against 11.7 percent for semaglutide alone in the same study — though CagriSema's rollout has been complicated by the arrival of even newer rivals, with at least one market commentator describing it as risking obsolescence before it fully launches. Lilly's retatrutide, a triple agonist working on GLP-1, GIP and glucagon receptors simultaneously, is in trials not just for obesity but for knee osteoarthritis, on the theory that less weight on a joint changes the disease course.

The third is the drugs' indications creeping well outside diabetes and obesity. Zepbound is now approved for obstructive sleep apnoea, cutting breathing-interruption events by up to 62.8 percent in trials — the first drug ever approved for that condition. Wegovy carries an indication for a liver disease called MASH and for cardiovascular risk reduction. What began as a diabetes drug, then became a weight-loss drug, is increasingly being sold and studied as a general metabolic-disease platform.

So, should you take one?

The honest answer depends less on the drug than on who's asking. If you have type 2 diabetes, or an obesity diagnosis with a related complication — high blood pressure, sleep apnoea, fatty liver, joint disease — these drugs are now mainstream, guideline-supported treatment, and the conversation belongs with an endocrinologist or physician who can weigh your specific risk factors, not a wellness clinic or an online seller.

If your weight is within a normal range and the goal is a cosmetic few kilograms, the calculation is weaker. None of the approved indications cover that use, the drugs are not risk-free, and the same muscle-loss, discontinuation-regain and cost issues apply to you as to anyone else — without the offsetting benefit of treating an actual metabolic disease.

Whatever the reason, buy only against a prescription from a licensed pharmacy, in original packaging with a checkable batch number — India's counterfeit risk is real and, with the price war underway, there is no longer a cost argument for buying from an unregulated source. Budget for more than the injection itself: protein intake and resistance training to protect muscle mass, periodic blood work, and a realistic expectation that stopping the drug means most people regain most of the weight within a year. And because India, for the moment, is running an unusual real-world experiment — a branded original, a licensed second brand, and dozens of generic versions of essentially the same molecule, sold side by side at prices spanning more than a ten-fold range — the useful question to bring to a doctor in 2026 isn't just "should I take a GLP-1 drug," but which molecule, which manufacturer, at what dose, and for how long. That conversation, unlike the price, hasn't gotten any simpler.

A note on sourcing

This account draws on FDA approval records and company disclosures from Novo Nordisk and Eli Lilly, peer-reviewed trial data published in JAMA Ophthalmology and The Lancet and its sister journals, the ICMR-INDIAB national study, and reporting from Reuters, FiercePharma, BioPharma Dive and other pharmaceutical trade press current to September 2026.